- Raised $3M Seed round led by Jackson Square Ventures, Nov 2025
About
GIT Therapeutics is transforming the future of healthcare by decoding oral drug delivery. Its breakthrough platform enables precise, sustained treatment – delivered exactly where and when it's needed, eliminating variability, reducing side effects, and replacing invasive therapies. The company's proprietary TARDIS oral delivery system uniquely targets the digestive system with sustained-release drug therapy to maximize clinical efficacy, minimize side effects, creating a paradigm shift in therapeutic outcomes, unlocking new market potential in precision medicine. By obtaining targeted, time controlled sustained release therapy, GIT Therapeutics aims to address critical unmet needs across major multi-billion-dollar markets, including Parkinson's disease, MS, IBD (Crohn's, Ulcerative Colitis), GI infections (H. Pylori, CDI), Celiac disease, and Obesity management.
Funding history · 1 round · $3.0M total
Q&A
- What is GIT Therapeutics' primary focus?
- GIT Therapeutics is focused on redefining the future of oral drug delivery through its breakthrough platform that enables precise, sustained treatment.
- What is the name of GIT Therapeutics' proprietary drug delivery system?
- The company's proprietary system is called TARDIS, an oral delivery system designed to target the digestive system with sustained-release drug therapy.
- Which medical conditions does GIT Therapeutics aim to address with its TARDIS system?
- GIT Therapeutics aims to address critical unmet needs in conditions such as Parkinson’s disease, MS, IBD (Crohn’s, Ulcerative Colitis), GI infections (H. Pylori, CDI), Celiac disease, and Obesity management.
- When was GIT Therapeutics founded?
- GIT Therapeutics was founded in October 2024.
- Where is GIT Therapeutics headquartered?
- GIT Therapeutics is headquartered in Tel Aviv-Yafo, Israel.
- How many employees does GIT Therapeutics currently have?
- GIT Therapeutics has 1-10 employees.
- Who are the co-founders of GIT Therapeutics?
- The co-founders of GIT Therapeutics are Erez Cohn (Co-Founder & CEO), Avshalom Ben Manachem (Co-Founder & CTO), and Ilan Zalit Zalit (Co-founder & CSO).
- What is the current funding stage of GIT Therapeutics?
- GIT Therapeutics is currently in the Pre-Funding stage.
- Does GIT Therapeutics hold any patents?
- Yes, GIT Therapeutics holds 1 patent.
Team · 3
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/106481672/ |
Identifiers & details
| Legal name | GIT THERAPEUTICS LTD |
|---|---|
| Founded | 2024-10 |
| Employees (exact) | 3 |
Radar intelligence
Patents
| EPO | 1 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 517054029 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2024-10-13 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Active charges / liens | 0 |
| Registry events | 1 — violation (1) |
| Registered address | זית 8 ראש העין |
Recent registry events
| Date | Event |
|---|---|
| 2026-06-01 | עדכון הפרה |